New spinal fluid test aims to solve dementia misdiagnosis puzzle
NCT ID NCT07166744
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test whether measuring a specific abnormal protein (alpha-synuclein) in spinal fluid can reliably distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease. Researchers will collect samples and perform cognitive tests on 286 older adults with suspected DLB or Alzheimer's. A better diagnostic test could prevent dangerous medication errors in DLB patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a reliable diagnostic test for dementia with Lewy bodies, reducing misdiagnosis and preventing harmful treatments.
- What could go wrong
- This is an observational study, not a treatment trial. The test may not prove accurate enough in real-world settings, and results may not change clinical practice quickly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may hold clues to depression – a new device listens in
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Could the sound of your voice reveal depression?
- Could a new pill for schizophrenia pass its first human test?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Could a new drug offer hope for Treatment-Resistant depression?